Cash Flow Statement

Amortizatization of Intangibles Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Free Cash Flow Gains from Investment Securities Net Cash Flow Net Income Other financing activities Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Prime Medicine (PRME) Change in Receivables (2024 - 2025)

Prime Medicine (PRME) has disclosed Change in Receivables for 2 consecutive years, with -$120000.0 as the latest value for Q3 2025.